Axa
MIRM icon

Axa’s Mirum Pharmaceuticals MIRM Stock Holding History

Axa’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-351,682
Closed -$17.9M – 664
2025
Q2 		$17.9M Buy
351,682
+310
+0.1% +$13.8K 0.05% 298
2025
Q1 		$15.8M Sell
351,372
-74,274
-17% -$3.5M 0.05% 308
2024
Q4 		$17.6M Sell
425,646
-422
-0.1% -$17.6K 0.05% 298
2024
Q3 		$16.6M Buy
426,068
+76
+0% +$3.03K 0.05% 310
2024
Q2 		$14.6M Sell
425,992
-167,794
-28% -$4.4M 0.04% 327
2024
Q1 		$14.9M Buy
593,786
+73
+0% +$2.01K 0.04% 331
2023
Q4 		$17.5M Sell
593,713
-23,402
-4% -$708K 0.06% 297
2023
Q3 		$19.5M Sell
617,115
-51,760
-8% -$1.42M 0.07% 277
2023
Q2 		$17.3M Sell
668,875
-219,679
-25% -$5.84M 0.06% 311
2023
Q1 		$21.3M Sell
888,554
-57,984
-6% -$1.32M 0.07% 286
2022
Q4 		$18.5M Buy
946,538
+88,327
+10% +$1.75M 0.07% 318
2022
Q3 		$18M Sell
858,211
-28,188
-3% -$679K 0.07% 299
2022
Q2 		$17.2M Sell
886,399
-97,430
-10% -$2.3M 0.06% 324
2022
Q1 		$21.7M Sell
983,829
-8,726
-0.9% -$178K 0.06% 347
2021
Q4 		$15.8M Buy
992,555
+140,383
+16% +$2.18M 0.04% 408
2021
Q3 		$17M Buy
852,172
+190,580
+29% +$3.1M 0.05% 370
2021
Q2 		$11.4M Buy
661,592
+92,610
+16% +$1.66M 0.03% 485
2021
Q1 		$11.3M Buy
568,982
+263,496
+86% +$5.04M 0.03% 492
2020
Q4 		$5.33M Buy
305,486
+77,496
+34% +$1.52M 0.02% 678
2020
Q3 		$4.39M Buy
227,990
+60,950
+36% +$1.31M 0.02% 662
2020
Q2 		$3.25M Buy
167,040
+10,289
+7% +$172K 0.01% 724
2020
Q1 		$2.19M Buy
+156,751
New +$2.57M 0.01% 714

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Axa's MIRM Position: Q3 2025 in Review

Axa sold out of Mirum Pharmaceuticals (MIRM) in Q3 2025, closing a stake of 351,682 shares — an estimated $17.9M sold.

Axa first reported a position in MIRM in Q1 2020 and held it in 22 quarters. The position peaked at $21.7M in Q1 2022. 272 funds tracked by Wall St. Rank hold MIRM as of Q3 2025.

  • Axa reported no remaining Mirum Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Axa sold 351,682 Mirum Pharmaceuticals shares in Q3 2025, an estimated $17.9M.
  • Axa first reported a position in Mirum Pharmaceuticals in Q1 2020 and held it in 22 quarters.
  • Axa's Mirum Pharmaceuticals position peaked at $21.7M in Q1 2022.
  • 272 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.